Canagliflozin/metformin
Canagliflozin/metformin, sold under the brand name Vokanamet among others, is a fixed-dose combination anti-diabetic medication used for the treatment of type 2 diabetes.[2][1][3] It is used in combination with diet and exercise.[2][1][3] It is taken by mouth.[2][1][3]
| Combination of | |
|---|---|
| Canagliflozin | SGLT2 inhibitor |
| Metformin | Biguanide |
| Clinical data | |
| Trade names | Vokanamet, Invokamet |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
It was approved for use in the European Union in April 2014,[2][1] and for use in the United States in August 2014.[4]
Adverse effects
To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin, and empagliflozin should each be stopped at least three days before, and ertugliflozin should be stopped at least four days before scheduled surgery.[5]
Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.[5]
References
- "Vokanamet 50 mg/850 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 13 February 2020. Retrieved 2 March 2020.
- "Vokanamet EPAR". European Medicines Agency (EMA). 18 February 2020. Retrieved 2 March 2020.
- "Invokamet- canagliflozin and metformin hydrochloride tablet, film coated Invokamet XR- canagliflozin and metformin hydrochloride tablet, film coated, extended release". DailyMed. 5 February 2020. Retrieved 2 March 2020.
- "Drug Approval Package: Invokamet (canagliflozin and metformin hydrochloride) Tablets NDA #204353". U.S. Food and Drug Administration (FDA). 4 September 2014. Retrieved 2 March 2020.
- "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration (FDA). 19 March 2020. Retrieved 6 June 2020.
This article incorporates text from this source, which is in the public domain.
Further reading
- Davidson JA, Sloan L (January 2017). "Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview". Adv Ther. 34 (1): 41–59. doi:10.1007/s12325-016-0434-2. PMC 5216068. PMID 27854055.
External links
- "Canagliflozin mixture with Metformin". Drug Information Portal. U.S. National Library of Medicine.
- "FDA revises label of diabetes drug canagliflozin". U.S. Food and Drug Administration (FDA). 15 January 2016.
- "FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)". U.S. Food and Drug Administration (FDA). 18 May 2016.
- "FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)". U.S. Food and Drug Administration (FDA). 17 June 2016.
- "FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate". U.S. Food and Drug Administration (FDA). 9 May 2017.
- "Warning use metformin in certain patients with reduced kidney function". U.S. Food and Drug Administration (FDA). 14 November 2017.
- "Warning: infection of genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 7 September 2018.